Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 309.41 |
| Open | 308.47 |
| Bid | 306.40 x 100 |
| Ask | 306.65 x 100 |
| Day's Range | 304.38 - 311.86 |
| 52 Week Range | 211.71 - 329.72 |
| Volume | |
| Avg. Volume | 2,728,390 |
| Market Cap | 164.417B |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 43.85 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 9.00 (2.94%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
- Zacks
Top Stock Reports for Apple, Mastercard & Amgen
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Mastercard (MA) and Amgen (AMGN), as well as two micro-cap stocks Utah Medical Products, Inc. (UTMD) and Bridger Aerospace Group Holdings, Inc. (BAER).
- Zacks
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen are included in this Analyst Blog.
- Zacks
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
© 2024 Yahoo. All rights reserved.